IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)

Trial Profile

IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs AGS 004 (Primary) ; Vorinostat (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VORVAX
  • Most Recent Events

    • 06 Sep 2017 According to an Argos Therapeutics Inc media release, four patients currently enrolled in the trial have received AGS-004 manufactured using RNA antigens derived from infectious plasma collected from the patient prior to the initiation of antiretroviral therapy (ART). The most recently enrolled patient is receiving, and all future patients will receive, AGS-004 manufactured with RNA antigens amplified directly from the patient's own latent viral reservoir.
    • 06 Sep 2017 According to an Argos Therapeutics Inc media release, for the first time a patient in this trial has been dosed with AGS-004 dendritic cell therapy manufactured utilizing RNA antigens from the patient's latent viral reservoir.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top